Medical Pharmacology: Chapter 41 — Anti-Inflammatory Drugs -- Module 2 — NSAID Toxicity, Drug Interactions, and Special Populations

Chapter 41 — Anti-Inflammatory Drugs — Module 2 — NSAID Toxicity, Drug Interactions, and Special Populations

1. A 69-year-old woman with atrial fibrillation (AF, an irregular heart rhythm) is maintained on warfarin with a target INR (international normalized ratio, a measure of anticoagulant effect) of 2.0 to 3.0. Her last INR 3 weeks ago was 2.6. She presents to clinic reporting new-onset knee pain for which she began self-medicating with piroxicam (a long-acting non-selective NSAID) 3 weeks ago. Her INR today is 5.1. She has no signs of active bleeding. Her creatinine and LFTs (liver function tests) are normal. Which of the following most accurately identifies the pharmacological reason piroxicam is particularly high-risk when combined with warfarin, and represents the most appropriate immediate management?

A) Piroxicam has caused warfarin toxicity through a pharmacodynamic mechanism: piroxicam's potent COX-1 (cyclooxygenase-1) inhibition depletes TXA2 (thromboxane A2) in platelets and simultaneously activates the extrinsic coagulation cascade by exposing subendothelial collagen at NSAID-damaged mucosal sites, generating thrombin that paradoxically consumes circulating clotting factors and elevates the INR through a consumption coagulopathy.
B) Piroxicam has elevated the INR by displacing warfarin from plasma albumin binding sites with high affinity; piroxicam's high protein binding (greater than 99%) produces near-complete albumin saturation, forcing all co-administered warfarin into the unbound free fraction and acutely tripling its anticoagulant activity; the appropriate management is plasmapheresis to rapidly remove the unbound warfarin.
C) Piroxicam's plasma half-life of 30 to 86 hours provides sustained COX-1 inhibition with prolonged platelet dysfunction persisting throughout the dosing interval, and piroxicam is a CYP2C9 (cytochrome P450 2C9, the hepatic enzyme responsible for metabolizing the more pharmacologically active S-enantiomer of warfarin) inhibitor that reduces S-warfarin clearance, raising warfarin plasma concentrations and the INR; management involves holding warfarin, rechecking INR in 24 to 48 hours, and discontinuing piroxicam; vitamin K administration should be considered given the INR of 5.1 in the absence of active bleeding.
D) Piroxicam has caused the INR elevation by directly inhibiting hepatic vitamin K epoxide reductase (VKOR, the enzyme that recycles vitamin K and is the target of warfarin), producing additive anticoagulant effect through the same biochemical target as warfarin; the combination produces twice the VKOR inhibition of warfarin alone, explaining the disproportionate INR elevation.
E) Piroxicam elevates the INR exclusively through its GI mucosal erosive effect: occult GI bleeding from piroxicam-induced mucosal ulceration causes chronic blood loss that depletes iron stores, producing iron-deficiency anemia that reduces erythrocyte-mediated vitamin K transport to the liver, impairing hepatic synthesis of vitamin K-dependent coagulation factors and raising the INR.

ANSWER: C

Rationale:

Piroxicam is a particularly high-risk NSAID in patients on warfarin for two compounding reasons related to its pharmacological properties. First, piroxicam has an exceptionally long plasma half-life of 30 to 86 hours — the longest of any commonly used NSAID — which means that once-daily dosing provides sustained, near-continuous plasma drug concentrations that maintain COX-1 inhibition throughout the entire dosing interval. This produces prolonged platelet dysfunction without the recovery windows between doses that occur with shorter-acting agents (ibuprofen, diclofenac), substantially amplifying the pharmacodynamic GI bleeding risk when combined with anticoagulation. Second, piroxicam — along with phenylbutazone and some other NSAIDs — inhibits CYP2C9, the hepatic cytochrome P450 enzyme predominantly responsible for oxidative metabolism of S-warfarin (the more pharmacologically active enantiomer). CYP2C9 inhibition reduces S-warfarin clearance, raising its plasma concentration and producing a pharmacokinetic elevation in the INR that compounds the pharmacodynamic bleeding risk. For an INR of 5.1 in the absence of active bleeding, current guidelines (American College of Chest Physicians) recommend holding warfarin and administering low-dose oral vitamin K (1 to 2.5 mg) to bring the INR back into the therapeutic range more quickly than holding alone; the INR should be rechecked in 24 to 48 hours and warfarin restarted at a lower dose once the INR falls below 3.0. Piroxicam should be discontinued and replaced with a safer analgesic.

Option A: Option A is incorrect because NSAIDs do not activate the extrinsic coagulation cascade or cause consumption coagulopathy; INR elevation with warfarin-NSAID combinations is due to pharmacokinetic (CYP2C9 inhibition raising S-warfarin levels) and pharmacodynamic (additive bleeding risk) mechanisms, not thrombin-mediated factor consumption.
Option B: Option B is incorrect because while piroxicam is highly protein-bound, albumin displacement as a sustained mechanism of clinically significant INR elevation is not pharmacologically valid — displacement interactions produce transient free drug increases that are rapidly cleared by increased distribution and elimination; plasmapheresis is not indicated for supratherapeutic INR from a drug interaction.
Option D: Option D is incorrect because piroxicam and other NSAIDs do not inhibit vitamin K epoxide reductase (VKOR); VKOR inhibition is the specific mechanism of warfarin and other coumarin anticoagulants — NSAIDs have no known VKOR inhibitory activity.
Option E: Option E is incorrect because NSAID-induced occult GI bleeding does not elevate the INR through iron-deficiency anemia impairing vitamin K transport; this proposed mechanism (erythrocyte vitamin K transport depletion) is not physiologically established, and the INR elevation in this patient is pharmacokinetic and pharmacodynamic in origin.

2. A 55-year-old man with moderate persistent asthma and nasal polyposis (noncancerous growths in the nasal passages) presents for elective laparoscopic cholecystectomy (surgical removal of the gallbladder). His medical history includes documented AERD (aspirin-exacerbated respiratory disease, also called Samter triad), with a prior episode of severe bronchospasm after ibuprofen use. The anesthesiologist's standard multimodal analgesic protocol includes ketorolac 15 mg IV (intravenous) at the end of surgery for postoperative pain control. The pharmacist flags this order. Which of the following best explains why ketorolac is contraindicated in this patient and identifies the safest alternative intraoperative/postoperative NSAID analgesic if one is required?

A) Ketorolac is a potent non-selective COX-1 (cyclooxygenase-1) inhibiting NSAID; in patients with AERD, any agent that inhibits COX-1 removes PGE2 (prostaglandin E2)-mediated restraint on airway mast cells and redirects arachidonic acid (AA) flux into the 5-LOX (5-lipoxygenase) pathway, causing a surge in cysteinyl leukotrienes that triggers bronchoconstriction; ketorolac administered intravenously is as capable of triggering AERD as any oral COX-1 inhibitor, because the mechanism is systemic and not route-dependent; if an NSAID analgesic is specifically required, IV celecoxib (where available) or rectal indomethacin alternative should be replaced with a non-COX-1 approach — acetaminophen IV is the appropriate non-opioid alternative.
B) Ketorolac is contraindicated because it is structurally related to aspirin and shares the same salicylate pharmacophore that cross-reacts with IgE anti-salicylate antibodies in AERD patients; the IV route bypasses GI absorption and delivers a large bolus of salicylate antigen directly to pulmonary mast cells via the bronchial circulation, triggering an immediate IgE-mediated anaphylactic reaction more severe than the oral route.
C) Ketorolac is contraindicated specifically in the perioperative setting because general anesthesia upregulates COX-2 expression in airway smooth muscle; ketorolac's potent COX-2 inhibition in this upregulated state produces paradoxical bronchodilation at normal doses but bronchoconstriction at the 15 mg IV dose used for postoperative analgesia, a dose-dependent biphasic airway effect unique to the anesthetic context.
D) Ketorolac is contraindicated because it inhibits platelet COX-1 irreversibly by the same covalent acetylation mechanism as aspirin; in AERD patients, irreversible platelet COX-1 inhibition causes a permanent depletion of platelet-derived PGE2 that sustains leukotriene overproduction for 7 to 10 days after a single ketorolac dose, making perioperative exposure especially dangerous due to the prolonged airway reactivity.
E) Ketorolac is contraindicated in AERD specifically because it undergoes pulmonary first-pass metabolism after IV administration, generating a reactive epoxide metabolite that covalently binds to 5-LOX in bronchial epithelial cells and constitutively activates leukotriene synthesis; this irreversible 5-LOX activation is unique to ketorolac among NSAIDs and explains why it is specifically prohibited in AERD even when other COX-1 inhibitors are cautiously permitted.

ANSWER: A

Rationale:

Ketorolac is a potent non-selective NSAID that inhibits both COX-1 and COX-2 reversibly, with particularly strong COX-1 inhibitory activity. In AERD, the triggering mechanism depends entirely on COX-1 inhibition in the respiratory mucosa — regardless of the drug's route of administration, chemical structure, or whether it is delivered orally, rectally, intramuscularly, or intravenously. When any COX-1 inhibitor reaches the systemic circulation, it inhibits COX-1 in airway epithelial cells, removing the baseline PGE2-mediated suppression of airway mast cells and eosinophils and simultaneously diverting arachidonic acid flux into the 5-LOX pathway, causing a surge in cysteinyl leukotrienes (LTC4, LTD4, LTE4) that triggers bronchoconstriction within 30 to 180 minutes. IV ketorolac produces this systemic COX-1 inhibition as effectively as oral ibuprofen — the IV route does not protect against AERD reactions and may actually produce a faster onset due to more rapid systemic bioavailability. Ketorolac must therefore be avoided entirely in AERD patients. For non-opioid postoperative analgesia in this patient, intravenous acetaminophen (paracetamol IV) is the appropriate choice — it provides effective analgesia without COX-1 inhibition in the respiratory mucosa and does not trigger AERD at standard doses. Celecoxib (which spares COX-1 at therapeutic doses) could also be considered if oral administration is feasible postoperatively, under appropriate supervision given rare cross-reactions in severe AERD.

Option B: Option B is incorrect because AERD is not an IgE-mediated hypersensitivity to salicylates; ketorolac is not chemically a salicylate, AERD patients do not have anti-salicylate IgE antibodies, and the mechanism is pharmacodynamic (COX-1 inhibition causing leukotriene shunting), not immunological.
Option C: Option C is incorrect because general anesthesia does not specifically upregulate COX-2 in airway smooth muscle in a way that changes ketorolac's bronchial pharmacology, and ketorolac does not have a dose-dependent biphasic airway effect — bronchodilation at low doses and bronchoconstriction at 15 mg is not an established pharmacological property.
Option D: Option D is incorrect because ketorolac inhibits platelet COX-1 reversibly, not irreversibly by covalent acetylation; irreversible acetylation is unique to aspirin. Ketorolac's platelet COX-1 inhibition resolves as the drug is cleared, not over 7 to 10 days.
Option E: Option E is incorrect because ketorolac does not undergo pulmonary first-pass metabolism or generate a reactive epoxide that covalently activates 5-LOX; AERD reactions to IV ketorolac are triggered by the same systemic reversible COX-1 inhibition mechanism as oral NSAIDs — there is no unique pulmonary metabolic activation pathway for ketorolac.

3. A 78-year-old woman with hypertension managed on lisinopril 10 mg daily and hydrochlorothiazide (HCTZ) 25 mg daily presents with 3 days of decreased urine output and bilateral leg edema. She started ibuprofen 400 mg three times daily 10 days ago for shoulder pain. Her laboratory results: serum creatinine 3.2 mg/dL (baseline 1.1 mg/dL 4 months ago), potassium 5.6 mEq/L (normal 3.5–5.0 mEq/L), BUN (blood urea nitrogen, a waste product cleared by the kidneys) 68 mg/dL. Urinalysis shows no casts or proteinuria. Which of the following most accurately identifies the mechanism of her acute kidney injury (AKI), predicts its expected course, and describes appropriate immediate management?

A) She has developed membranous nephropathy (an immune-mediated glomerular disease) from ibuprofen; the absence of proteinuria on urinalysis makes this unlikely to resolve with drug discontinuation alone and she will require immunosuppressive therapy with corticosteroids; lisinopril and HCTZ are not contributory to her renal presentation.
B) She has developed acute tubular necrosis (ATN, death of renal tubular cells from ischemia or toxins) from ibuprofen's direct nephrotoxic metabolites accumulating in the proximal tubule; ATN from NSAIDs is typically irreversible and she will likely require long-term renal replacement therapy; the appropriate management is urgent hemodialysis initiation.
C) She has developed analgesic nephropathy (chronic tubulointerstitial kidney damage from prolonged mixed analgesic abuse) from 10 days of ibuprofen use; the structural renal damage is permanent, explaining the marked creatinine rise; management requires renal biopsy before any therapy is initiated to determine the degree of irreversible fibrosis.
D) She has an NSAID-exacerbated prerenal azotemia (reduced kidney perfusion causing elevated waste products) caused exclusively by HCTZ-induced volume depletion; ibuprofen is not contributory because its prostaglandin-inhibitory renal effects occur only when GFR is below 30 mL/min/1.73m²; management is IV fluid resuscitation while continuing all current medications.
E) She has hemodynamic AKI from the triple whammy combination: ibuprofen removes prostaglandin-mediated afferent arteriolar vasodilation, lisinopril blocks angiotensin II-dependent efferent arteriolar constriction that normally compensates for reduced afferent tone, and HCTZ causes volume depletion that further reduces renal perfusion pressure; this form of AKI is typically reversible with drug discontinuation and supportive care; ibuprofen should be stopped immediately, lisinopril and HCTZ should be held temporarily, IV fluids given if volume-depleted, and renal function rechecked in 24 to 48 hours.

ANSWER: E

Rationale:

This patient has a textbook presentation of triple whammy hemodynamic AKI. The three-drug combination acts on three separate determinants of glomerular filtration rate (GFR) simultaneously. First, ibuprofen suppresses renal prostaglandin synthesis, removing PGE2 (prostaglandin E2)-mediated afferent arteriolar vasodilation — the compensatory mechanism that maintains GFR when renal perfusion pressure is reduced. Second, lisinopril (an ACE inhibitor) blocks angiotensin II-mediated efferent arteriolar constriction: the efferent arteriole normally constricts in response to reduced afferent perfusion to maintain glomerular hydrostatic pressure (the driving force for filtration), and ACE inhibitor therapy removes this compensatory response. Third, hydrochlorothiazide causes volume depletion, reducing renal perfusion pressure and increasing dependence on both prostaglandin and angiotensin II-mediated compensatory mechanisms — both of which have now been pharmacologically disabled. The clinical features support hemodynamic AKI: rapid onset after NSAID initiation, no urinary casts or significant proteinuria (ruling out glomerulonephritis and acute tubular necrosis), and no prior analgesic abuse history. Hemodynamic AKI is typically fully reversible with timely drug discontinuation and supportive care. Ibuprofen should be stopped immediately as the initiating agent; lisinopril and HCTZ should be temporarily held to allow renal perfusion to recover; volume status should be assessed and IV fluids administered if she is intravascularly depleted; renal function and electrolytes (particularly the potassium of 5.6 mEq/L, which reflects reduced aldosterone-mediated K+ excretion from the ACE inhibitor + NSAID combination) should be monitored closely.

Option A: Option A is incorrect because membranous nephropathy presents with nephrotic-range proteinuria (usually >3.5 g/day) and hypoalbuminemia — this patient's urinalysis shows no proteinuria, making a glomerular disease diagnosis inconsistent with the clinical picture, and the acute 10-day time course following NSAID initiation strongly points to hemodynamic AKI.
Option B: Option B is incorrect because NSAID-associated ATN is not a recognized clinical entity — NSAIDs cause hemodynamic AKI through prostaglandin suppression, not through direct tubular cell death from nephrotoxic metabolites; urinary casts would be expected in ATN and are absent here, and hemodynamic AKI is reversible with drug discontinuation, not requiring dialysis.
Option C: Option C is incorrect because analgesic nephropathy requires years of heavy mixed analgesic abuse to produce chronic tubulointerstitial nephritis and papillary necrosis; 10 days of ibuprofen monotherapy does not cause analgesic nephropathy, and biopsy is not needed — the temporal relationship and clinical pattern point clearly to hemodynamic AKI.
Option D: Option D is incorrect because ibuprofen is clearly contributory through its prostaglandin-inhibitory mechanism, which operates at any level of GFR in patients with physiological stress states — the threshold of eGFR below 30 mL/min/1.73m² is the absolute contraindication threshold, not the threshold at which prostaglandin-dependent renal perfusion becomes relevant.

4. A 44-year-old man with bipolar I disorder (a mood disorder with episodes of mania and depression) has been stable on lithium carbonate 900 mg twice daily for 3 years, with serum lithium levels consistently between 0.8 and 1.0 mEq/L (therapeutic range 0.6–1.2 mEq/L). Two weeks ago his orthopedist prescribed indomethacin 50 mg three times daily for acute gouty arthritis (a form of inflammatory arthritis caused by uric acid crystals). He now presents to the emergency department with coarse hand tremor, confusion, and unsteady gait (ataxia). His serum lithium level is 2.1 mEq/L. Temperature is 37.2°C. Which of the following most accurately identifies the cause of his lithium toxicity, explains why indomethacin carries the highest risk of this interaction among NSAIDs, and describes the most appropriate acute management?

A) He has developed lithium toxicity from a pharmacokinetic interaction in which indomethacin inhibits hepatic CYP3A4 (cytochrome P450 3A4, a liver metabolizing enzyme), markedly reducing lithium's hepatic clearance and raising its serum concentration; indomethacin carries the highest risk because it is the most potent CYP3A4 inhibitor among NSAIDs; management is activated charcoal administration to reduce ongoing lithium absorption.
B) He has developed lithium toxicity because indomethacin — the NSAID with the most potent renal prostaglandin suppression among commonly used agents — reduces renal prostaglandin-dependent renin release, decreasing angiotensin II and aldosterone-mediated sodium excretion, which increases proximal tubular sodium (and parallel lithium) reabsorption and reduces renal lithium clearance; indomethacin raises lithium levels more than other NSAIDs; acute management includes stopping both indomethacin and lithium, providing IV hydration to increase renal lithium excretion, and monitoring lithium levels every 4 to 6 hours until below 1.2 mEq/L.
C) He has developed serotonin syndrome (a dangerous excess of serotonergic activity) from an indomethacin-lithium pharmacodynamic interaction; indomethacin's COX-2 inhibition in serotonergic neurons of the raphe nuclei (brainstem serotonin-producing cells) blocks serotonin reuptake, and the combination with lithium's serotonin-augmenting effects produces the classic triad of tremor, altered mental status, and autonomic instability; management is cyproheptadine (a serotonin antagonist).
D) He has developed lithium toxicity from a pharmacodynamic interaction: indomethacin directly displaces lithium from intracellular sodium-potassium ATPase (Na⁺/K⁺-ATPase) pump binding sites in renal tubular cells, preventing active lithium secretion into the tubular lumen and causing accumulation; indomethacin has the highest affinity for Na⁺/K⁺-ATPase among NSAIDs, explaining its disproportionate effect on lithium clearance compared to ibuprofen or naproxen.
E) He has developed lithium toxicity because indomethacin causes renal tubular acidosis type IV (a condition where the kidney cannot excrete acid normally), reducing urinary pH to below 5.5 and converting lithium carbonate to lithium chloride in the distal tubule; the uncharged lithium chloride form is highly lipid-soluble and undergoes extensive passive reabsorption in the collecting duct, increasing lithium reabsorption and raising serum levels.

ANSWER: B

Rationale:

This patient has lithium toxicity (serum level 2.1 mEq/L; toxic threshold >1.5 mEq/L) from the NSAID-lithium drug interaction, precipitated by indomethacin — the NSAID documented to produce the largest increase in lithium plasma concentrations among commonly used agents. The mechanism operates through renal prostaglandin suppression: renal prostaglandins (particularly PGE2) normally stimulate renin secretion from juxtaglomerular cells; NSAID-mediated suppression of these prostaglandins reduces renin release, lowering angiotensin II, which reduces aldosterone secretion. Because aldosterone-independent sodium reabsorption increases when prostaglandin-dependent natriuresis is removed, proximal tubular sodium reabsorption increases — and since lithium is partially reabsorbed alongside sodium in the proximal tubule (sharing the sodium reabsorption pathway), lithium clearance falls and plasma levels rise. Indomethacin causes the most pronounced renal prostaglandin suppression among commonly used NSAIDs, producing the largest magnitude increase in lithium levels (up to 60% or more) compared to agents such as sulindac (least effect) or ibuprofen (intermediate). His lithium level of 2.1 mEq/L with neurotoxic symptoms (coarse tremor, confusion, ataxia) represents moderate-to-severe toxicity. Acute management requires: stopping both indomethacin and lithium immediately; IV normal saline hydration to increase renal perfusion and tubular flow, which enhances lithium clearance; serial lithium levels every 4 to 6 hours; and close monitoring for progression to severe toxicity (seizures, cardiac arrhythmias). Hemodialysis is indicated if levels exceed 3.5 mEq/L with severe symptoms or if renal function is impaired.

Option A: Option A is incorrect because lithium is not metabolized by hepatic CYP enzymes — it is an inorganic ion eliminated exclusively by renal excretion without hepatic biotransformation; indomethacin's interaction with lithium is renal, not hepatic.
Option C: Option C is incorrect because this presentation is lithium toxicity, not serotonin syndrome; serotonin syndrome features hyperthermia, clonus, hyperreflexia, and diaphoresis — this patient is afebrile and his symptoms (coarse tremor, ataxia, confusion) are characteristic of lithium neurotoxicity. Indomethacin does not inhibit serotonin reuptake.
Option D: Option D is incorrect because NSAIDs do not displace lithium from Na⁺/K⁺-ATPase binding sites; the NSAID-lithium interaction is mediated by reduced renal prostaglandin-dependent renin and aldosterone signaling, not by direct competition for tubular pump binding sites.
Option E: Option E is incorrect because NSAIDs do not cause renal tubular acidosis type IV through the described mechanism, and lithium reabsorption is not governed by urinary pH or lipid-solubility of a chloride salt form — lithium handling is ionic and tubular, dependent on sodium cotransport in the proximal tubule.

5. A 26-year-old woman at 26 weeks and 4 days of gestation was started on indomethacin 50 mg orally every 8 hours 5 days ago as a tocolytic agent (a drug used to slow or stop preterm labor contractions) for threatened preterm labor. Today's routine obstetric ultrasound monitoring shows the amniotic fluid index (AFI, a measure of total amniotic fluid volume) has decreased from 18 cm (normal) at the start of therapy to 9 cm (borderline low; oligohydramnios defined as AFI below 5 cm). Fetal Doppler (ultrasound blood flow assessment) shows no evidence of ductal constriction. She has not had uterine contractions for 3 days. Which of the following best describes the significance of the declining AFI and the most appropriate clinical response?

A) The declining AFI is expected and clinically insignificant during indomethacin tocolysis; amniotic fluid volume always falls during tocolytic therapy because all tocolytic agents reduce fetal urine output through a shared renal prostaglandin mechanism, and monitoring can be safely discontinued once contractions have stopped for 48 hours.
B) The declining AFI represents normal physiological variation and is not related to indomethacin; at 26 weeks, fetal renal prostaglandin synthesis is negligible and indomethacin cannot reduce fetal GFR (glomerular filtration rate) or fetal urine output; ultrasound measurement of amniotic fluid is inherently imprecise at this gestational age and the finding should not prompt any change in therapy.
C) The declining AFI confirms that indomethacin has caused irreversible fetal renal tubular dysfunction; the appropriate response is immediate delivery by emergency cesarean section to prevent further fetal renal damage, because continuing indomethacin beyond 5 days invariably leads to permanent neonatal renal failure requiring postnatal dialysis.
D) The declining AFI is an early warning sign of indomethacin-induced fetal renal prostaglandin suppression reducing fetal urine output, which is the primary source of amniotic fluid from mid-pregnancy onward; since contractions have stopped and the indication for tocolysis is no longer active, indomethacin should be discontinued now; if further tocolysis is needed, an alternative tocolytic (such as a beta-2 agonist or calcium channel blocker) should be used; fetal renal function and amniotic fluid volume typically recover fully after drug discontinuation.
E) The declining AFI combined with absence of ductal constriction on Doppler confirms that indomethacin is selectively inhibiting fetal renal COX-2 without affecting ductal COX-1; this selective organ effect at 26 weeks indicates that the drug has achieved its therapeutic target and the AFI decline should prompt dose reduction to 25 mg every 8 hours rather than discontinuation, maintaining tocolytic benefit while reducing renal side effects.

ANSWER: D

Rationale:

The declining AFI from 18 cm to 9 cm over 5 days of indomethacin tocolysis is a clinically significant finding that represents early indomethacin-induced fetal renal prostaglandin suppression reducing fetal urine output — the mechanism underlying NSAID-associated oligohydramnios in pregnancy. From mid-pregnancy onward, fetal urine production is the primary source of amniotic fluid, and fetal renal prostaglandins (PGE2 and PGI2) contribute to maintaining fetal GFR and renal blood flow. When indomethacin crosses the placenta and suppresses fetal renal prostaglandin synthesis, fetal urine output falls, reducing amniotic fluid volume. The AFI of 9 cm is borderline — oligohydramnios is defined as AFI below 5 cm — but the trend is clearly downward and warrants action. Crucially, in this patient the primary indication for indomethacin (preterm labor) has resolved: she has had no contractions for 3 days. There is no longer a compelling reason to continue a drug that is showing early signs of fetal renal suppression when its therapeutic purpose has been achieved. Indomethacin should be stopped. If tocolysis is still needed for ongoing uterine irritability, alternative agents that do not share the fetal renal prostaglandin mechanism — such as nifedipine (a calcium channel blocker) or terbutaline (a beta-2 agonist) — are appropriate choices. After indomethacin is stopped, fetal renal function and amniotic fluid volume typically recover within 24 to 72 hours, because the mechanism is hemodynamic prostaglandin suppression (reversible) rather than structural renal tubular injury.

Option A: Option A is incorrect because declining AFI during indomethacin tocolysis is a recognized adverse fetal effect that requires clinical attention — it is not expected, insignificant, or universal to all tocolytic agents; other tocolytic agents (nifedipine, atosiban, betamimetics) do not suppress fetal renal prostaglandins.
Option B: Option B is incorrect because at 26 weeks fetal renal prostaglandin synthesis is sufficiently active to be suppressed by indomethacin, producing fetal urine output reduction; the 2020 FDA drug safety communication about NSAIDs warns of fetal renal dysfunction from 20 weeks onward, confirming that fetal renal effects are pharmacologically real at this gestational age.
Option C: Option C is incorrect because indomethacin-induced AFI decline represents reversible fetal renal hemodynamic suppression, not irreversible tubular injury requiring emergency delivery; the appropriate response is drug discontinuation with monitoring, not cesarean section — particularly at 26 weeks when prematurity itself carries severe morbidity.
Option E: Option E is incorrect because indomethacin does not selectively inhibit fetal renal COX-2 while sparing ductal COX-1; it is a non-selective COX inhibitor, and the absence of ductal constriction on Doppler at 26 weeks reflects the lower ductal prostaglandin dependence at this gestational age (before 28 to 32 weeks), not selective COX isoform targeting.

6. A 61-year-old woman with rheumatoid arthritis (RA) has been managed on weekly oral methotrexate (MTX) 22.5 mg for 2 years with good disease control and stable CBC (complete blood count) values. Three weeks ago her internist (who was unaware of her MTX therapy) prescribed naproxen 500 mg twice daily for low back pain. She now presents with painful mouth sores, fatigue, and new bruising. Laboratory results: WBC (white blood cell count) 1,800/μL (normal >4,000), platelets 68,000/μL (normal >150,000), creatinine 1.4 mg/dL (baseline 0.9 mg/dL). Which of the following most accurately identifies the cause of her presentation and the appropriate management?

A) She has developed NSAID-induced aplastic anemia (complete bone marrow failure) from naproxen; naproxen causes direct bone marrow toxicity through COX-1 inhibition in hematopoietic progenitor cells, impairing prostaglandin-dependent erythroid and myeloid differentiation; management requires immediate discontinuation of naproxen and bone marrow transplant evaluation.
B) She has developed methotrexate hepatotoxicity from chronic low-dose MTX accumulation; the naproxen interaction has accelerated hepatic MTX polyglutamate deposition in hepatocytes (liver cells), causing hepatocellular injury that impairs synthesis of all blood cell lineages; management includes liver biopsy to quantify fibrosis before deciding whether to continue MTX.
C) She has developed MTX toxicity from naproxen-mediated impairment of renal MTX excretion: naproxen competitively inhibits OAT (organic anion transporter) proteins in the proximal tubule that secrete MTX, and simultaneously reduces GFR (glomerular filtration rate) through renal prostaglandin suppression, prolonging MTX exposure at a rheumatology dose (22.5 mg/week) that is above the threshold where this interaction becomes clinically significant; the resulting myelosuppression (pancytopenia) and mucositis reflect MTX toxicity, not naproxen direct toxicity; management includes stopping naproxen and MTX, administering leucovorin (folinic acid rescue, which bypasses the MTX block on folate synthesis) to rescue myelosuppressed cells, and close monitoring of CBC and renal function.
D) She has developed naproxen-induced immune thrombocytopenic purpura (ITP, a condition where the immune system destroys platelets) combined with naproxen-induced neutropenia through separate immune-mediated mechanisms; both complications are entirely explained by naproxen alone and MTX is not involved; management requires stopping naproxen and starting corticosteroids for the immune-mediated platelet and neutrophil destruction.
E) She has developed a drug-induced lupus (DIL, a lupus-like syndrome caused by certain drugs) reaction from the naproxen-MTX combination; DIL from this combination is characterized by pancytopenia, mucositis, and renal impairment through immune complex deposition in the glomeruli and bone marrow; management requires antinuclear antibody (ANA) testing and hydroxychloroquine therapy.

ANSWER: C

Rationale:

This patient has methotrexate toxicity precipitated by naproxen-mediated impairment of renal MTX excretion. While the interaction between NSAIDs and high-dose oncology MTX (greater than 50 to 100 mg/m² per cycle) is widely recognized as potentially life-threatening, the same interaction also occurs at higher rheumatology doses — her weekly dose of 22.5 mg is at the upper end of the rheumatology range (standard range 7.5 to 25 mg/week), where clinical guidelines specifically note that NSAID co-administration should be approached with caution and some recommend withholding NSAIDs for 24 to 48 hours around the weekly dose. NSAIDs impair renal MTX clearance through two mechanisms: competitive inhibition of OAT1 and OAT3 (organic anion transporters) in the proximal tubule that actively secrete MTX into the tubular lumen, and reduction of GFR from renal prostaglandin suppression (her creatinine rise from 0.9 to 1.4 mg/dL confirms reduced renal function). The result is prolonged and elevated MTX plasma concentrations that cause the characteristic MTX toxicity syndrome: mucositis (oral ulcers from MTX's antiproliferative effect on rapidly dividing GI epithelial cells) and myelosuppression (pancytopenia from MTX-mediated folate synthesis inhibition in bone marrow precursor cells). Leucovorin (folinic acid) rescues cells by bypassing the DHFR (dihydrofolate reductase) block — it provides pre-reduced folate that does not require MTX-inhibited DHFR for utilization, allowing DNA synthesis to resume in myelosuppressed cells. Both naproxen and MTX should be stopped; the internist who prescribed naproxen should be informed of the MTX interaction to prevent recurrence; alternative analgesics (acetaminophen, topical agents) should be used in future.

Option A: Option A is incorrect because naproxen does not cause aplastic anemia through COX-1 inhibition in hematopoietic progenitors; the bone marrow suppression in this patient is MTX toxicity from elevated MTX exposure due to the drug interaction, not direct naproxen-mediated myelotoxicity.
Option B: Option B is incorrect because the presentation is acute MTX toxicity (mucositis + pancytopenia) from elevated MTX plasma levels due to impaired renal clearance, not chronic hepatic MTX polyglutamate accumulation causing blood cell synthesis impairment; MTX hepatotoxicity produces liver fibrosis and transaminase elevation, not acute pancytopenia.
Option D: Option D is incorrect because this is not NSAID-induced immune thrombocytopenia and neutropenia — the combination of mucositis, pancytopenia, and acute renal function decline is the clinical signature of MTX toxicity, not coincident immune-mediated drug reactions from naproxen alone.
Option E: Option E is incorrect because drug-induced lupus does not cause the acute mucositis and pancytopenia pattern seen here; drug-induced lupus typically presents with arthralgia, serositis, and rash, and the clinical picture here is entirely consistent with MTX toxicity.

7. A 58-year-old man with CKD (chronic kidney disease) stage 4 (eGFR 28 mL/min/1.73m², a severely reduced kidney filtering capacity) and diabetic nephropathy presents requesting an oral NSAID (non-steroidal anti-inflammatory drug) for knee osteoarthritis. His primary care physician considers prescribing celecoxib, reasoning that its COX-2 (cyclooxygenase-2) selectivity will spare renal prostaglandins because "the kidney mainly uses COX-1." Which of the following most accurately assesses whether this reasoning is pharmacologically correct, and identifies the appropriate management?

A) The physician's reasoning is incorrect: both COX-1 and COX-2 contribute to renal prostaglandin synthesis, and renal cells — including glomerular mesangial cells, afferent arteriolar cells, the macula densa (a specialized kidney structure that senses tubular fluid composition), and medullary interstitial cells — constitutively express COX-2 as well as COX-1; celecoxib's selective COX-2 inhibition therefore does suppress renal prostaglandins and carries the same hemodynamic AKI risk as non-selective NSAIDs in patients with compromised renal function; oral NSAIDs including celecoxib are contraindicated at eGFR below 30 mL/min/1.73m²; topical diclofenac gel for the knee is the appropriate alternative if local analgesic delivery is needed.
B) The physician's reasoning is correct: renal prostaglandin synthesis in the glomerulus and afferent arteriole is exclusively COX-1-mediated, and celecoxib's COX-2 selectivity fully preserves all renal prostaglandins responsible for maintaining GFR (glomerular filtration rate) and renal blood flow; celecoxib is therefore safe to use at standard doses (200 mg daily) in patients with CKD stage 4, and no dose adjustment or additional monitoring is required.
C) The physician's reasoning is partially correct: COX-2 is expressed in the renal medullary collecting duct but not in the glomerulus or afferent arteriole; celecoxib therefore safely preserves glomerular and afferent arteriolar prostaglandins while only reducing medullary PGE2 (prostaglandin E2); this makes celecoxib a viable option in CKD stage 4 at half the standard dose (100 mg daily) with monthly creatinine monitoring.
D) The physician's reasoning is irrelevant because celecoxib's renal risk in CKD comes not from prostaglandin suppression but from celecoxib's sodium-retaining effect, which is a COX-2-independent property unique to sulfonamide-containing NSAIDs; since sodium retention worsens CKD progression through increased glomerular hydrostatic pressure, celecoxib should be avoided in CKD exclusively for this sodium-retention reason, not for prostaglandin-related hemodynamic AKI.
E) The physician's reasoning is correct that celecoxib spares renal COX-1, but celecoxib is still contraindicated in CKD stage 4 for a different reason: its COX-2 inhibition in the renal medullary interstitium suppresses PGE2-mediated water excretion via aquaporin-2 (AQP2, a water channel in the collecting duct), causing severe hyponatremia (low blood sodium) rather than AKI in CKD patients with reduced tubular diluting capacity.

ANSWER: A

Rationale:

The physician's reasoning contains a pharmacological error with significant clinical consequences. COX-2 is not absent from the kidney — it is constitutively expressed in several renal cell types, including glomerular mesangial cells, the macula densa of the juxtaglomerular apparatus, afferent arteriolar smooth muscle cells, and medullary interstitial cells. This renal COX-2 contributes to the synthesis of PGE2 and PGI2 (prostacyclin) that help maintain renal blood flow and GFR in physiologically stressed states — including the chronically stressed state of advanced CKD with diabetic nephropathy, where renal perfusion is already marginal and prostaglandin-dependent afferent arteriolar vasodilation is critical. Celecoxib's selective COX-2 inhibition therefore impairs renal prostaglandin synthesis in these COX-2-expressing renal cells, producing the same hemodynamic AKI risk as non-selective NSAIDs in patients with compromised renal function. This patient's eGFR of 28 mL/min/1.73m² is below the 30 mL/min/1.73m² threshold at which oral NSAIDs — including celecoxib — are considered contraindicated. Prescribing any oral NSAID, regardless of COX selectivity, at this level of renal function risks precipitating AKI that could accelerate progression to end-stage renal disease. Topical diclofenac gel (1%), which achieves systemic bioavailability of approximately 6 to 10% of an oral equivalent dose, is the appropriate analgesic alternative for localized knee pain in this patient — it delivers effective local analgesia with substantially lower systemic exposure and dramatically reduced renal prostaglandin suppression.

Option B: Option B is incorrect because COX-2 is constitutively expressed in the glomerulus, afferent arteriole, and macula densa and contributes to renal prostaglandin synthesis; the claim that renal prostaglandins responsible for maintaining GFR are exclusively COX-1-derived is pharmacologically inaccurate, and celecoxib is not safe at eGFR below 30 mL/min/1.73m².
Option C: Option C is incorrect because COX-2 is not restricted to the renal medullary collecting duct — it is expressed in glomerular, afferent arteriolar, and juxtaglomerular structures as well; the proposed schema of COX-2 being limited to the medullary compartment is anatomically incorrect, and dose reduction to 100 mg daily does not make celecoxib safe in CKD stage 4.
Option D: Option D is incorrect because celecoxib's renal risk in CKD is substantially mediated by prostaglandin suppression causing hemodynamic AKI — this is the established mechanism; the sulfonamide structure of celecoxib does cause some sodium retention, but this is not a COX-2-independent mechanism separate from prostaglandin suppression, and this option incorrectly dismisses the central prostaglandin-mediated hemodynamic risk.
Option E: Option E is incorrect because celecoxib's renal risk is hemodynamic AKI from afferent arteriolar prostaglandin suppression, not primarily AQP2-mediated hyponatremia; severe hyponatremia is not the primary or characteristic adverse renal effect of celecoxib in CKD patients.

8. A 72-year-old man with atrial fibrillation (AF) on apixaban (a DOAC, direct oral anticoagulant inhibiting factor Xa) and depression on sertraline (an SSRI, selective serotonin reuptake inhibitor) presents to the emergency department with hematemesis (vomiting blood) and melena (black tarry stools indicating upper GI bleeding). He started ibuprofen 600 mg three times daily 5 days ago for knee pain. Vital signs: blood pressure 94/62 mmHg, heart rate 118 bpm. Hemoglobin is 7.2 g/dL (normal >13 g/dL in men). Which of the following most accurately identifies the mechanisms contributing to this bleeding event and the most critical immediate management priority?

A) This bleeding is caused exclusively by apixaban anticoagulation; ibuprofen and sertraline are not contributing because ibuprofen does not impair platelet function at the 600 mg dose and SSRIs do not have clinically significant effects on platelet aggregation; the most critical immediate priority is administration of andexanet alfa (the specific reversal agent for factor Xa inhibitors) to restore coagulation.
B) This bleeding reflects ibuprofen-induced GI mucosal ulceration with hemorrhage; apixaban and sertraline are not contributing to the severity because DOACs (direct oral anticoagulants) do not increase GI bleeding risk when mucosal injury from NSAIDs is already present, and sertraline has been on board for longer than 2 weeks and has therefore already been metabolically cleared from platelet SERT receptors; the priority is PPI administration and endoscopy.
C) This bleeding is caused by a serotonin syndrome-induced coagulopathy from the sertraline-ibuprofen combination; ibuprofen's COX-2 inhibition in serotonergic neurons releases excess serotonin systemically, which at high concentrations activates thrombin and triggers disseminated intravascular coagulation (DIC, a condition of uncontrolled simultaneous clotting and bleeding); the priority is cyproheptadine administration.
D) This bleeding represents warfarin-SSRI synergistic coagulopathy; sertraline inhibits CYP2C9 and raises the effective warfarin (anticoagulant) concentration by blocking its metabolism; however this patient is on apixaban rather than warfarin, making sertraline's CYP2C9 inhibition irrelevant, and the bleeding is solely from ibuprofen mucosal damage without any pharmacodynamic contribution from apixaban or sertraline.
E) Three simultaneous mechanisms are contributing: ibuprofen has caused GI mucosal erosions and impaired platelet COX-1-dependent TXA2 (thromboxane A2) synthesis (reducing primary hemostasis); sertraline has depleted platelet serotonin via SERT (serotonin reuptake transporter) blockade (further impairing platelet activation through a second independent pathway); and apixaban has impaired secondary hemostasis by blocking factor Xa (preventing fibrin clot stabilization); the immediate priority is hemodynamic resuscitation with IV fluids and blood transfusion to stabilize the patient, followed by urgent endoscopy for diagnosis and hemostasis, and consideration of andexanet alfa or 4-factor PCC (prothrombin complex concentrate) for DOAC reversal given hemodynamic instability.

ANSWER: E

Rationale:

This patient's upper GI hemorrhage with hemodynamic instability (hypotension and tachycardia) represents a life-threatening bleeding event driven by three simultaneous and mechanistically independent contributions to hemostatic failure. First, ibuprofen has caused GI mucosal erosions and ulcerations by depleting COX-1-derived prostaglandins that protect gastric and duodenal epithelium — creating the bleeding source — while also reversibly inhibiting platelet COX-1-dependent TXA2 synthesis, impairing the platelet contribution to primary hemostasis at the mucosal injury site. Second, sertraline has progressively depleted platelet serotonin stores by blocking SERT over the weeks to months of therapy; platelet serotonin normally amplifies platelet aggregation via 5-HT2A receptor activation after initial platelet activation, and its depletion impairs this second independent platelet activation pathway — the SSRI-NSAID combination studies show 3 to 15-fold increase in upper GI bleeding risk through this dual platelet mechanism. Third, apixaban has blocked factor Xa, preventing the conversion of prothrombin to thrombin and impairing fibrin clot formation — so even when a platelet plug partially forms at the mucosal erosion, fibrin cannot reinforce and stabilize it. These three mechanisms simultaneously impair mucosal barrier integrity, primary platelet hemostasis (via two independent pathways), and secondary coagulation-based hemostasis. The immediate priority in a hypotensive patient is hemodynamic resuscitation: large-bore IV access, crystalloid and blood product transfusion to restore perfusion pressure and oxygen-carrying capacity; followed by urgent upper endoscopy for diagnosis and endoscopic hemostasis; and consideration of reversal of apixaban given hemodynamic instability (andexanet alfa is the specific reversal agent, or 4-factor PCC if andexanet is unavailable).

Option A: Option A is incorrect because ibuprofen at 600 mg three times daily does significantly impair platelet function through COX-1 inhibition, and sertraline does have clinically meaningful effects on platelet activation through platelet serotonin depletion — both are contributing mechanisms, not bystanders.
Option B: Option B is incorrect because DOACs increase GI bleeding risk when combined with NSAIDs through the pharmacodynamic impairment of fibrin clot stabilization, regardless of pre-existing mucosal injury; and sertraline's platelet serotonin depletion is not "metabolically cleared" — it persists as long as sertraline is taken because platelets continuously take up serotonin from plasma and sertraline continuously blocks that reuptake.
Option C: Option C is incorrect because this is upper GI bleeding from mucosal erosion with hemostatic failure, not serotonin syndrome; ibuprofen does not release serotonin from neurons, and DIC from serotonin excess is not an established mechanism — this confuses two entirely unrelated clinical entities.
Option D: Option D is incorrect because apixaban is not warfarin and sertraline's CYP2C9 inhibition is irrelevant to apixaban (which is CYP3A4-metabolized); more critically, this option falsely dismisses the pharmacodynamic contributions of both sertraline (platelet serotonin depletion) and apixaban (factor Xa inhibition impairing fibrin formation) to the bleeding event.

9. A 67-year-old woman with compensated alcoholic cirrhosis (Child-Pugh A, the mildest stage of cirrhosis severity) and mild portal hypertension (elevated pressure in the portal vein) was prescribed diclofenac 75 mg twice daily by an orthopedic surgeon for shoulder bursitis (inflammation of the fluid-filled sacs cushioning the shoulder joint). At her 6-week follow-up, she reports fatigue but no jaundice. Laboratory results: ALT (alanine aminotransferase, a liver enzyme) 224 U/L (normal upper limit 56 U/L; current value is 4× ULN), AST (aspartate aminotransferase, a liver enzyme) 198 U/L (3.5× ULN). Her baseline ALT 2 months ago was 48 U/L. Bilirubin and INR (international normalized ratio) remain normal. Which of the following most accurately identifies the cause of her transaminase elevation and describes the appropriate management and safer analgesic alternative?

A) Her transaminase elevation reflects disease progression of her underlying alcoholic cirrhosis triggered by diclofenac-mediated upregulation of hepatic alcohol dehydrogenase (ADH, the enzyme that metabolizes ethanol to acetaldehyde); diclofenac should be continued at the same dose, and serial liver biopsies every 3 months are required to assess fibrosis progression before any medication change is considered.
B) Her transaminase elevation is most likely diclofenac-induced hepatotoxicity: diclofenac undergoes CYP2C9 and CYP3A4-mediated formation of a reactive acyl glucuronide metabolite that can trigger immune-mediated hepatocellular injury, and elevations above 3× ULN are the established threshold for drug discontinuation; in a patient with underlying cirrhosis, hepatic metabolic reserve is reduced and the threshold for serious diclofenac hepatotoxicity is lower; diclofenac should be stopped immediately; acetaminophen at a reduced maximum dose of 2 g/day is generally safer in stable Child-Pugh A cirrhosis than NSAIDs for ongoing pain management.
C) Her transaminase elevation is an expected pharmacological effect of any NSAID in patients with cirrhosis: all NSAIDs cause dose-proportional transaminase elevations in cirrhotic patients through COX-1 inhibition reducing hepatic prostaglandin-mediated blood flow, and elevations of 3 to 5× ULN do not require drug discontinuation unless accompanied by jaundice or coagulopathy; diclofenac should be dose-reduced to 50 mg twice daily and transaminases rechecked in 4 weeks.
D) Her transaminase elevation reflects an interaction between diclofenac and residual dietary ethanol: diclofenac inhibits hepatic aldehyde dehydrogenase (ALDH, the enzyme responsible for ethanol metabolism beyond the acetaldehyde step), causing toxic acetaldehyde accumulation in hepatocytes even from trace dietary ethanol exposure; management requires stopping diclofenac and testing for alcohol relapse.
E) Her transaminase elevation is caused by diclofenac's displacement of endogenous bilirubin from albumin binding sites, causing unconjugated bilirubin to enter hepatocytes and trigger free radical-mediated hepatocellular oxidative stress; the diagnosis is confirmed by the absence of jaundice (because bilirubin enters cells rather than accumulating in plasma) and management requires N-acetylcysteine (NAC) infusion to replenish hepatic glutathione.

ANSWER: B

Rationale:

This patient's transaminase elevation — 4× ULN for ALT and 3.5× ULN for AST — above her baseline of 48 U/L, developing over 6 weeks of diclofenac therapy, is consistent with diclofenac-induced hepatotoxicity. Diclofenac carries the most clearly characterized hepatotoxicity signal among NSAIDs, and elevations above 3× ULN are the established clinical threshold requiring drug discontinuation regardless of symptom status. The mechanism involves CYP2C9 and CYP3A4-mediated formation of diclofenac-1-O-acyl glucuronide, a reactive metabolite that is protein-reactive and can trigger immune-mediated hepatocellular injury in susceptible individuals. In a patient with pre-existing cirrhosis, hepatic metabolic capacity for reactive metabolite detoxification is reduced, potentially lowering the threshold for serious hepatocellular injury. Stopping diclofenac immediately is mandatory. For ongoing pain management in a patient with Child-Pugh A cirrhosis, acetaminophen at a reduced maximum dose (2 g/day rather than the usual 3 to 4 g/day maximum, with further reduction to 1 to 2 g/day in active heavy alcohol use) is the preferred analgesic alternative — it is safer than oral NSAIDs in stable compensated cirrhosis because it does not impair renal prostaglandins (preventing AKI and hepatorenal syndrome), does not worsen platelet dysfunction (which is already impaired by portal hypertension and hypersplenism), and does not cause GI mucosal injury. She should be closely monitored with repeat LFTs after diclofenac discontinuation to confirm transaminase normalization.

Option A: Option A is incorrect because diclofenac does not upregulate hepatic alcohol dehydrogenase; the transaminase elevation is a recognized hepatotoxic drug effect of diclofenac itself, not alcohol metabolism alteration — continuing diclofenac above the hepatotoxicity threshold is clinically inappropriate.
Option C: Option C is incorrect because transaminase elevations above 3× ULN from diclofenac do require drug discontinuation regardless of the presence of jaundice or coagulopathy; this is the established monitoring rule, and dose reduction is not an accepted alternative to stopping the drug when this threshold is exceeded.
Option D: Option D is incorrect because diclofenac does not inhibit hepatic aldehyde dehydrogenase; diclofenac hepatotoxicity is mediated by reactive acyl glucuronide formation, not by interference with ethanol metabolism pathways, and acetaldehyde accumulation from ALDH inhibition is the mechanism of disulfiram — not NSAIDs.
Option E: Option E is incorrect because diclofenac hepatotoxicity is not caused by albumin-bilirubin displacement leading to hepatocellular oxidative stress; the mechanism is CYP-mediated reactive metabolite formation triggering immune-mediated hepatocellular injury, and N-acetylcysteine is not indicated for diclofenac hepatotoxicity (its indication is acetaminophen overdose with NAPQI-mediated hepatic glutathione depletion).

10. A 38-year-old woman with AERD (aspirin-exacerbated respiratory disease, also called Samter triad) and severe asthma underwent successful aspirin desensitization 6 months ago and has been taking aspirin 81 mg daily since then. At her last visit 2 months ago she reported significantly reduced nasal polyp burden (smaller noncancerous growths in her nasal passages) and improved sense of smell. Last week she traveled internationally and forgot her aspirin for 4 days. On day 5, she took her usual aspirin 81 mg and within 90 minutes developed wheezing, rhinorrhea (runny nose), and periocular pruritus (itching around the eyes) requiring rescue bronchodilator use. She presents to her allergist asking why she reacted to a dose of aspirin that she had been tolerating for 6 months. Which of the following most accurately explains what happened?

A) She has developed a new IgE-mediated aspirin allergy de novo during her 6 months of aspirin desensitization therapy; the daily aspirin exposure sensitized her immune system to aspirin as a hapten-protein conjugate, and the 4-day interruption allowed IgE antibody titers to peak; her reaction on day 5 represents a classic IgE-mediated type I hypersensitivity reaction that will now persist permanently.
B) Her 6 months of aspirin therapy caused irreversible downregulation of EP2 receptors (prostaglandin E receptor subtype 2) on her airway mast cells; the 4-day interruption allowed receptor expression to recover to pre-desensitization levels, and COX-1-independent EP2 receptor upregulation is now required before aspirin can be safely restarted; she needs a new full desensitization protocol.
C) She developed tolerance reversal because the 4-day interruption allowed platelet COX-1 enzyme to be replaced by new platelet production from megakaryocytes; the desensitization-induced tolerance operates through irreversible aspirin acetylation of platelet COX-1, and once new unacetylated platelets replace the old population over 4 days, the platelets can again respond to aspirin by generating a leukotriene-inducing TXA2 surge.
D) Aspirin desensitization-induced tolerance is not permanent — it requires continuous daily aspirin to be maintained; when aspirin is withheld for more than 72 hours (3 days), the pharmacodynamic suppression of the cysteinyl leukotriene pathway dissipates and full AERD reactivity returns; when she restarted aspirin on day 5 after a 4-day gap, she effectively administered a re-challenge dose to a patient who had reverted to full AERD reactivity, triggering the characteristic leukotriene-mediated reaction; she needs to undergo re-desensitization before resuming daily aspirin.
E) Her reaction reflects a class effect of COX-1 inhibitors that cannot be suppressed by desensitization; the aspirin desensitization provided only partial tolerance for 6 months, and the 4-day gap allowed the partial tolerance to collapse permanently; she is now refractory to re-desensitization and must switch to a selective COX-2 inhibitor for all future analgesic and anti-inflammatory needs.

ANSWER: D

Rationale:

This clinical scenario illustrates the critical pharmacological property of aspirin desensitization-induced tolerance: it is pharmacodynamic and requires continuous uninterrupted daily aspirin to be maintained. The mechanism of desensitization-induced tolerance involves sustained downregulation of the cysteinyl leukotriene synthesis pathway — including reduced expression and activity of 5-LOX (5-lipoxygenase) and LTC4 synthase in airway mast cells and eosinophils — achieved through continuous prostaglandin pathway modulation by ongoing aspirin-mediated COX-1 inhibition. When aspirin is withheld for more than 72 hours, the leukotriene pathway recovers to its constitutively overactive pre-desensitization state: 5-LOX expression and LTC4 synthase activity return to baseline, mast cell and eosinophil activation thresholds revert, and full AERD reactivity is restored. The patient's 4-day gap (96 hours) exceeded the 72-hour tolerance window, meaning that on day 5 when she took her usual 81 mg dose, she was no longer a desensitized patient taking a maintenance dose — she was effectively an AERD patient receiving a de novo aspirin challenge. The dose of 81 mg was sufficient to trigger COX-1 inhibition, leukotriene shunting, and the characteristic AERD bronchoconstriction. She will need to undergo re-desensitization before resuming daily aspirin. During this interval she should use a COX-2 selective agent or acetaminophen for analgesic needs. Her prior successful desensitization and the benefits she experienced (reduced polyp burden, improved olfaction) confirm she is a good candidate for re-desensitization.

Option A: Option A is incorrect because AERD is not IgE-mediated; desensitization does not sensitize the immune system to produce aspirin-specific IgE, and the reaction on day 5 is a pharmacodynamic leukotriene-shunting reaction, not IgE-mediated anaphylaxis — skin prick and specific IgE testing would be negative.
Option B: Option B is incorrect because desensitization-induced tolerance is not mediated by irreversible EP2 receptor downregulation that requires re-expression after interruption; the tolerance mechanism is ongoing pharmacodynamic suppression of the leukotriene pathway that dissipates rapidly without daily aspirin.
Option C: Option C is incorrect because desensitization tolerance operates through leukotriene pathway suppression, not through irreversible platelet COX-1 acetylation; aspirin's irreversible platelet effect is relevant to antiplatelet therapy but is not the mechanism of AERD desensitization tolerance — platelet TXA2 does not drive AERD reactions.
Option E: Option E is incorrect because AERD desensitization does not provide only partial tolerance that becomes permanently refractory after a gap; re-desensitization after a tolerance lapse is a well-established and effective procedure — the same desensitization protocol is repeated in a monitored setting, and tolerance can be re-established successfully.

11. A 63-year-old man has been taking celecoxib 200 mg daily for knee osteoarthritis (OA, degenerative joint disease) for 18 months without GI (gastrointestinal) complaints. His cardiologist, following a new diagnosis of hypertension and metabolic syndrome (a cluster of cardiovascular risk factors), prescribes low-dose aspirin 81 mg daily for primary cardiovascular prevention. The pharmacy counsels him that adding aspirin will reduce celecoxib's GI protective advantage and recommends adding a PPI (proton pump inhibitor, an acid-suppressing agent). He is puzzled because he understands celecoxib "protects the stomach" and asks why aspirin changes this. Which of the following most accurately explains the pharmacological basis for the pharmacist's advice?

A) Low-dose aspirin activates COX-2 in gastric epithelial cells, paradoxically stimulating excess PGE2 (prostaglandin E2) production that overwhelms celecoxib's COX-2 inhibitory effect at the mucosal surface; the resulting PGE2 excess causes parietal cell acid hypersecretion by activating EP3 receptors (prostaglandin E receptor subtype 3), increasing GI ulcer risk despite celecoxib co-administration.
B) Low-dose aspirin competitively displaces celecoxib from gastric mucosal COX-2 binding sites, restoring full COX-2 activity in gastric epithelial cells; this paradoxically upregulates COX-2-derived PGE2 in the mucosa to supraphysiological levels, increasing mucosal blood flow to the point of submucosal hemorrhage that presents as NSAID gastropathy.
C) Celecoxib's GI advantage depends on leaving mucosal COX-1 intact and functioning: by sparing COX-1, celecoxib preserves constitutive PGE2 and PGI2 synthesis in gastric epithelial cells that maintains mucosal defense; low-dose aspirin irreversibly acetylates gastric mucosal COX-1, depleting the prostaglandins that celecoxib's COX-2 selectivity was preserving; with COX-1 now inhibited by aspirin, celecoxib's gastroprotective rationale is eliminated and the patient has the equivalent of a non-selective NSAID without GI protection; adding a PPI is appropriate to restore gastroprotection.
D) Low-dose aspirin reduces celecoxib's GI advantage because aspirin's irreversible platelet COX-1 inhibition prevents TXA2-mediated vasoconstriction of gastric submucosal arterioles; paradoxically, improved mucosal blood flow from TXA2 deficiency dilates mucosal capillaries to the point of capillary fragility, making the mucosa prone to spontaneous bleeding at the dilated sites; celecoxib cannot counteract this aspirin-induced capillary fragility because it only affects COX-2.
E) Low-dose aspirin eliminates celecoxib's GI advantage through a pharmacokinetic interaction: aspirin acetylates gastric mucosal esterases (enzymes that degrade ester bonds) that normally hydrolyze celecoxib to its inactive form in the gastric lumen; with esterase inactivation, celecoxib accumulates in the gastric mucosa at toxic concentrations that directly damage epithelial cells through a non-prostaglandin mechanism.

ANSWER: C

Rationale:

Celecoxib's GI protective advantage over non-selective NSAIDs derives entirely from its COX-2 selectivity preserving gastric mucosal COX-1 activity. The gastric mucosa depends on COX-1-derived prostaglandins — primarily PGE2 (prostaglandin E2) and PGI2 (prostacyclin) — to maintain all four components of mucosal defense: mucus and bicarbonate secretion, mucosal blood flow, inhibition of parietal cell acid secretion, and epithelial repair. By selectively inhibiting COX-2 and leaving COX-1 intact, celecoxib allows continued constitutive prostaglandin synthesis from the mucosal COX-1 that protects the gastric epithelium. When low-dose aspirin is added, aspirin irreversibly acetylates COX-1 throughout the body — including in gastric mucosal epithelial cells, mucus-secreting cells, and submucosal endothelium. This irreversible COX-1 inhibition by aspirin eliminates the prostaglandin synthesis that celecoxib was preserving; the mucosa now has both COX-1 (from aspirin) and COX-2 (from celecoxib) inhibited, a state essentially equivalent to a non-selective NSAID with no gastroprotective advantage. This is the pharmacological basis for the well-documented clinical finding that celecoxib's GI benefit in the CLASS (Celecoxib Long-Term Arthritis Safety Study) trial was demonstrable in patients not taking aspirin but was absent in patients taking concurrent low-dose aspirin. The pharmacist's recommendation to add a PPI is correct: with celecoxib's GI advantage eliminated, PPI co-therapy is needed to provide gastroprotection through acid suppression.

Option A: Option A is incorrect because low-dose aspirin irreversibly inhibits gastric mucosal COX-2 (it irreversibly acetylates both COX-1 and COX-2 where it contacts them); aspirin does not activate COX-2 to produce excess PGE2, and this proposed acid hypersecretion mechanism through EP3 receptor activation does not reflect aspirin's pharmacology.
Option B: Option B is incorrect because aspirin covalently inactivates COX-2 rather than displacing celecoxib competitively; covalent acetylation is not reversible displacement, and aspirin-acetylated COX-2 does not produce supraphysiological PGE2 — it produces no PGE2 because the enzyme is permanently inactivated.
Option D: Option D is incorrect because aspirin's platelet TXA2 inhibition does not cause capillary fragility through arteriolodilation; TXA2 influences platelet aggregation and vasoconstriction systemically but does not produce the proposed mucosal capillary dilatory fragility mechanism.
Option E: Option E is incorrect because aspirin does not inactivate gastric mucosal esterases and celecoxib is not hydrolyzed to an inactive form by gastric esterases in the lumen; celecoxib's GI advantage is a pharmacodynamic COX selectivity mechanism, not a pharmacokinetic luminal inactivation mechanism.